adenoviral vector encoding rat her-2/neu
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2006 (NCT00307229)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adenoviral vector encoding rat her-2/neu
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00307229 | Phase 1 | Mar 1, 2006 | Canadian Breast Cancer Research Alliance, Hamilton Health Sciences Corporation, McGill University, McMaster University, Ontario Cancer Research Network |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Breast Cancer Research Alliance | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Hamilton Health Sciences Corporation | Academic/Hospital | 1 | 0 | 1 | 2006 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| McMaster University | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Ontario Cancer Research Network | Academic/Hospital | 1 | 0 | 1 | 2006 |
5 organizations
Page 1 / 1